32 results
Thumbnail

D2.490 - Consistent efficacy of a seasonal 300IR birch pollen sublingual immunotherapy in children and adolescents during worst pollen exposure: results of the YOBI trial

Thumbnail

D2.491 - Efficacy of a 300IR birch liquid sublingual immunotherapy during the alder and hazel pollen seasons: results of the YOBI trial

Thumbnail

D2.492 - Efficacy and safety of a 300IR daily dose of a SLIT of birch pollen allergen extract in children and adolescents with allergic rhinoconjunctivitis: results from the YOBI trial

Thumbnail

D2.494 - Tralokinumab treatment in adults with atopic dermatitis who were previously treated with dupilumab: 12-months real-world data from the TRACE study

Thumbnail

D2.495 - Treatment with Izicopan (INF904), an oral anti-C5aR inhibitor improves efficacy and safety in patients with chronic spontaneous urticaria: results from a Phase 2a study

Thumbnail

D2.496 - First-in-Human Phase I Clinical Outcomes of BxC-I17e Enriched with HSP70/miR-22-3p in Atopic Dermatitis

Thumbnail

D2.497 - Oral Deucrictibant Immediate-Release Capsule for On-Demand Treatment of Hereditary Angioedema Attacks: Results of the Phase 3 RAPIDe-3 Trial

Thumbnail

D2.498 - Berotralstat Decreased HAE Attacks Treated with On-Demand Therapy or Utilizing Professional Care in Pediatric Patients Aged 2 to

Thumbnail

D2.499 - Immunoregulatory Effects of Dupilumab Added to Omalizumab-Facilitated Multi-Allergen Oral Immunotherapy in the COMBINE clinical trial

Thumbnail

D2.503 - LP-003 Injection for the treatment of H1 Antihistamine-Inadequately Controlled Chronic Spontaneous Urticaria (CSU): A Multicenter, Randomized, Double-Blind, Controlled Phase Ⅱ Study

Thumbnail

D2.504 - Novel food supplement containing a combination of bioactive compounds in pediatric cow’s milk protein allergy: results from a randomized, placebo-controlled trial

Thumbnail

D3.17 - Outcomes of Anti-Tuberculosis Drug Reintroduction Following Adverse Drug Reactions among Adult Patients at a Tertiary Hospital in the Philippines (2022-2024)

Thumbnail

D3.27 - Nivolumab-Induced Psoriasiform Eruption: Diagnostic Challenge Between Immune-Related Toxicity and Drug Allergy

Thumbnail

D3.30 - Automated generation of structured clinical databases in drug hypersensitivity: real-world validation in patients with proton pump inhibitor reactions

Thumbnail

D3.16 - Increase of Post–SARS-CoV-2 Rashes Mimicking Penicillin Allergy in Children with Group A beta-hemolytic Streptococcus Infection: an emerging and challenging issue

Thumbnail

D3.18 - Role of an Allergological Work-up in Antibiotic Allergy Delabeling in Mexican Pediatric Patients

Thumbnail

D3.20 - Study of “in vitro” cross reactivity between nsLTP’s comparing “in silico” results with a new specific IgE test based on immunoblot methodology

Thumbnail

D3.21 - When the Patient Diagnoses Herself: Amoxicillin-Induced Acute Pancreatitis as a Rare Manifestation of Drug Hypersensitivity

Thumbnail

D3.25 - Machine learning models to differentiate cross-reactive and selective-hypersensitive patients to nonsteroidal anti-inflammatory drugs hypersensitivity

Thumbnail

D3.31 - Real-world Practices in the Diagnosis and Evaluation of Allergic Rhinitis among Korean Specialists